https://www.nasdaq.com/press-release/arcutis-biotherapeutics-secures-%24225-million-in-non-dilutive-debt-financing-from-slr
https://www.nasdaq.com/press-release/fda-accepts-arcutis-biotherapeutics-new-drug-application-for-roflumilast-cream-for
https://www.nasdaq.com/press-release/arcutis-appoints-mas-matsuda-as-general-counsel-and-corporate-secretary-2021-12-16
https://www.nasdaq.com/press-release/arcutis-announces-data-comparing-the-vehicle-in-investigational-roflumilast-cream
https://www.nasdaq.com/press-release/arcutis-to-present-at-upcoming-investor-conference-2021-11-10
https://www.nasdaq.com/press-release/arcutis-announces-third-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/arcutis-submits-topical-roflumilast-cream-new-drug-application-to-fda-for-the
https://www.nasdaq.com/press-release/new-data-highlighting-itch-reduction-with-topical-roflumilast-in-multiple
https://www.nasdaq.com/press-release/arcutis-expands-patent-portfolio-with-roflumilast-pharmacokinetics-patent-2021-09-28
https://www.nasdaq.com/press-release/new-topical-roflumilast-data-presented-at-the-european-academy-of-dermatology-and
https://www.nasdaq.com/press-release/arcutis-to-present-at-upcoming-investor-conferences-2021-09-09
https://www.nasdaq.com/press-release/arcutis-announces-appointment-of-keith-leonard-to-board-of-directors-2021-09-02
https://www.nasdaq.com/press-release/arcutis-enrolls-first-patient-in-phase-3-clinical-trial-of-topical-roflumilast-foam
https://www.nasdaq.com/press-release/bruce-binkowitz-joins-arcutis-as-vice-president-of-biometrics-2021-08-23
https://www.nasdaq.com/press-release/arcutis-announces-second-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/arcutis-announces-additions-to-its-investor-relations-and-communications-team-2021-08
https://www.nasdaq.com/press-release/arcutis-advances-science-of-psoriasis-drug-development-with-new-precision-method-for
https://www.nasdaq.com/press-release/arcutis-announces-first-patient-enrolled-in-phase-3-clinical-trial-of-topical
https://www.nasdaq.com/press-release/arcutis-provides-update-on-phase-2a-clinical-trial-evaluating-arq-252-cream-as-a
https://www.nasdaq.com/press-release/greg-sukay-joins-arcutis-as-vice-president-of-manufacturing-and-process-technologies
https://www.nasdaq.com/press-release/arcutis-announces-appointment-of-sue-jean-lin-to-board-of-directors-2021-06-09
https://www.nasdaq.com/press-release/rajvir-madan-joins-arcutis-as-chief-digital-and-information-officer-2021-06-01
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-showcases-pivotal-dermis-1-and-2-phase-3-trial-data-for
https://www.nasdaq.com/press-release/arcutis-announces-first-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/arcutis-to-present-new-roflumilast-cream-phase-3-data-at-the-european-academy-of
https://www.nasdaq.com/press-release/arcutis-to-present-at-the-2021-truist-securities-life-sciences-summit-2021-04-28
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-showcases-new-roflumilast-data-in-psoriasis-and-seborrheic
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-to-present-new-roflumilast-data-at-the-american-academy-of
https://www.nasdaq.com/press-release/arcutis-initiates-phase-3-clinical-trial-of-topical-roflumilast-cream-arq-151-as-a
https://www.nasdaq.com/press-release/arcutis-announces-updates-to-its-executive-team-2021-03-26
https://www.nasdaq.com/press-release/arcutis-announces-first-patient-enrolled-in-phase-2a-clinical-trial-evaluating-arq
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-to-showcase-long-term-safety-efficacy-and-patient-reported
https://www.nasdaq.com/press-release/arcutis-to-present-at-the-cowen-41st-annual-health-care-conference-2021-02-25
https://www.nasdaq.com/press-release/courtney-barton-joins-arcutis-as-chief-compliance-officer-and-chief-of-staff-2021-02
https://www.nasdaq.com/press-release/arcutis-announces-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-announces-closing-of-underwriters-over-allotment-option-in
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-announces-pricing-of-upsized-public-offering-of-common-stock
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-announces-proposed-public-offering-of-common-stock-2021-02-01
https://www.nasdaq.com/press-release/arcutis-announces-positive-topline-results-from-pivotal-dermis-1-and-2-phase-3-trials
https://www.nasdaq.com/press-release/arcutis-to-advance-topical-roflumilast-foam-arq-154-into-phase-3-development-for-the
https://www.nasdaq.com/press-release/arcutis-initiates-pivotal-phase-3-clinical-trials-evaluating-topical-roflumilast
https://www.nasdaq.com/press-release/matthew-moore-joins-arcutis-as-chief-business-officer-2021-01-11
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-added-to-nasdaq-biotechnology-index-2020-12-21
https://www.nasdaq.com/press-release/arcutis-highlights-advanced-pipeline-unique-immuno-dermatology-drug-development
https://www.nasdaq.com/press-release/arcutis-announces-last-patient-completes-final-study-visit-in-dermis-1-and-dermis-2
https://www.nasdaq.com/press-release/arcutis-to-host-virtual-investor-day-on-wednesday-december-9-2020-2020-12-02
https://www.nasdaq.com/press-release/data-from-long-term-safety-study-support-chronic-use-of-arq-151-topical-roflumilast
https://www.nasdaq.com/press-release/arcutis-announces-positive-topline-data-from-phase-2b-study-of-arq-154-topical
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-to-present-at-the-stifel-2020-virtual-healthcare-conference
https://www.nasdaq.com/press-release/arcutis-announces-third-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/arcutis-announces-appointment-of-terrie-curran-to-board-of-directors-2020-11-04
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-presents-new-positive-data-from-phase-2-studies-of-arq-151
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-to-present-new-data-from-arq-151-topical-roflumilast-cream
https://www.nasdaq.com/press-release/arcutis-completes-enrollment-in-phase-1-2b-study-evaluating-arq-252-in-chronic-hand
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-announces-closing-of-public-offering-and-concurrent-private
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-announces-pricing-of-public-offering-and-concurrent-private
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-announces-proposed-public-offering-and-concurrent-private
https://www.nasdaq.com/press-release/arcutis-announces-positive-topline-data-from-phase-2-clinical-trial-evaluating-arq
https://www.nasdaq.com/press-release/arcutis-completes-enrollment-in-dermis-1-and-dermis-2-pivotal-phase-3-clinical-trials
https://www.nasdaq.com/press-release/arcutis-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-2020-2020-09
https://www.nasdaq.com/press-release/arcutis-biotherapeutics-to-accelerate-arq-151-topical-roflumilast-cream-into-phase-3
https://www.nasdaq.com/press-release/arcutis-announces-second-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/arcutis-to-present-at-the-wedbush-pacgrow-healthcare-conference-2020-08-10
https://www.nasdaq.com/press-release/bethany-dudek-joins-arcutis-as-vice-president-of-quality-2020-08-04
https://www.nasdaq.com/press-release/the-journal-of-drugs-in-dermatology-publishes-results-from-positive-phase-1-2a-trial
https://www.nasdaq.com/press-release/preliminary-data-from-long-term-safety-study-support-chronic-use-of-arq-151-topical
https://www.nasdaq.com/press-release/arcutis-appoints-patrick-burnett-m.d.-ph.d.-faad-as-chief-medical-officer-2020-07-27
https://www.nasdaq.com/press-release/arcutis-enrolls-last-patient-in-phase-2b-clinical-trial-evaluating-arq-154-topical
https://www.nasdaq.com/press-release/the-new-england-journal-of-medicine-publishes-results-from-positive-phase-2b-trial-of
https://www.nasdaq.com/press-release/arcutis-initiates-patient-enrollment-in-the-phase-2b-portion-of-the-phase-1-2b-study
https://www.nasdaq.com/press-release/arcutis-enrolls-last-patient-in-phase-2-proof-of-concept-clinical-trial-evaluating
https://www.nasdaq.com/press-release/arcutis-to-present-at-the-goldman-sachs-41st-annual-global-health-care-conference
https://www.nasdaq.com/press-release/ayisha-jeter-joins-arcutis-as-vice-president-of-market-access-2020-06-01
https://www.nasdaq.com/press-release/jay-ramsinghani-joins-arcutis-as-vice-president-of-commercial-strategy-and-operations
https://www.nasdaq.com/press-release/arcutis-announces-first-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/halley-e.-gilbert-appointed-to-arcutis-board-of-directors-2020-04-27
https://www.nasdaq.com/press-release/arcutis-announces-enrollment-of-first-patient-in-phase-1-2b-study-of-arq-252-in
https://www.nasdaq.com/press-release/kimberly-lathroum-joins-arcutis-as-vice-president-of-marketing-2020-03-23
https://www.nasdaq.com/press-release/arcutis-announces-inclusion-of-children-in-on-going-pivotal-phase-3-clinical-trials
https://www.nasdaq.com/press-release/heather-rowe-armstrong-joins-arcutis-as-vice-president-of-investor-relations-and
